CO2017012830A2 - Compuestos de n-tieno [2,3-d] pirimidinil-d-fenilalanina, método de preparación de los mismos y composiciones farmacéuticas que los contienen - Google Patents
Compuestos de n-tieno [2,3-d] pirimidinil-d-fenilalanina, método de preparación de los mismos y composiciones farmacéuticas que los contienenInfo
- Publication number
- CO2017012830A2 CO2017012830A2 CONC2017/0012830A CO2017012830A CO2017012830A2 CO 2017012830 A2 CO2017012830 A2 CO 2017012830A2 CO 2017012830 A CO2017012830 A CO 2017012830A CO 2017012830 A2 CO2017012830 A2 CO 2017012830A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- preparation
- pharmaceutical compositions
- compositions containing
- thieno
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a nuevos derivados aminoácido, a un proceso para su preparación y a composiciones farmacéuticas que los contienen. Particularmente, los derivados de aminoácido tienen la fórmula (I), en la que R1, R2, R5, R6, R7, R12, X, Y, A, E y n son como se han definido en la descripción. Los compuestos de la presente invención tienen propiedades pro-apoptóticas lo que hace posible usarlos en patologías que implican un defecto en la apoptosis, tal como, por ejemplo, en el tratamiento del cáncer y de enfermedades inmunes y auto-inmunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1555747A FR3037956B1 (fr) | 2015-06-23 | 2015-06-23 | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/EP2016/064436 WO2016207226A1 (en) | 2015-06-23 | 2016-06-22 | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012830A2 true CO2017012830A2 (es) | 2018-03-28 |
Family
ID=54260901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012830A CO2017012830A2 (es) | 2015-06-23 | 2017-12-13 | Compuestos de n-tieno [2,3-d] pirimidinil-d-fenilalanina, método de preparación de los mismos y composiciones farmacéuticas que los contienen |
Country Status (42)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| CN110381937A (zh) * | 2017-01-06 | 2019-10-25 | 法国施维雅药厂 | Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物 |
| EA202090082A1 (ru) | 2017-06-22 | 2020-05-22 | Ле Лаборатуар Сервье | Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции |
| WO2019035899A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
| BR112020003180A2 (pt) | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
| CN110964034B (zh) * | 2018-09-29 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 |
| AR116635A1 (es) | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| TW202038960A (zh) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 |
| CN111187277B (zh) * | 2018-11-14 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體－藥物結合物及使用方法 |
| WO2020254299A1 (en) | 2019-06-17 | 2020-12-24 | Les Laboratoires Servier | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| AU2021385349A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96531A (en) * | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
| ES2616255T3 (es) * | 2008-04-30 | 2017-06-12 | National Health Research Institutes | Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas |
| WO2012044993A1 (en) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders |
| CN102464667B (zh) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | 一类五元杂环并嘧啶类化合物及其制备方法和用途 |
| AP3391A (en) * | 2010-12-20 | 2015-08-31 | Glenmark Pharmaceuticals Sa | 2-Amino-4-arylthiazole compounds as TROA1 antagonists |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2922858A4 (en) * | 2012-11-20 | 2016-06-15 | Univ Mcgill | THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND / OR GÉRANYLGÉRANYL PYROPHOSPHATE SYNTHASE |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2015
- 2015-06-23 FR FR1555747A patent/FR3037956B1/fr not_active Expired - Fee Related
-
2016
- 2016-06-16 UY UY0001036733A patent/UY36733A/es unknown
- 2016-06-22 CR CR20170571A patent/CR20170571A/es unknown
- 2016-06-22 LT LTEP16731158.8T patent/LT3313850T/lt unknown
- 2016-06-22 RU RU2018102372A patent/RU2747673C2/ru active
- 2016-06-22 TW TW105119598A patent/TWI631124B/zh active
- 2016-06-22 KR KR1020187002016A patent/KR102620905B1/ko active IP Right Grant
- 2016-06-22 US US15/737,783 patent/US10457687B2/en active Active
- 2016-06-22 UA UAA201800620A patent/UA123267C2/uk unknown
- 2016-06-22 CN CN201680039612.9A patent/CN107709334B/zh active Active
- 2016-06-22 MD MDE20180440T patent/MD3313850T2/ro unknown
- 2016-06-22 MA MA42232A patent/MA42232B1/fr unknown
- 2016-06-22 RS RS20181327A patent/RS57961B1/sr unknown
- 2016-06-22 CR CR20170590A patent/CR20170590A/es unknown
- 2016-06-22 PT PT16731158T patent/PT3313850T/pt unknown
- 2016-06-22 EP EP16731158.8A patent/EP3313850B1/en active Active
- 2016-06-22 AU AU2016282837A patent/AU2016282837B2/en active Active
- 2016-06-22 SI SI201630123T patent/SI3313850T1/sl unknown
- 2016-06-22 PE PE2017002702A patent/PE20190111A1/es unknown
- 2016-06-22 DK DK16731158.8T patent/DK3313850T3/en active
- 2016-06-22 ES ES16731158T patent/ES2703997T3/es active Active
- 2016-06-22 MX MX2017016996A patent/MX368845B/es active IP Right Grant
- 2016-06-22 CU CUP2017000164A patent/CU20170164A7/es unknown
- 2016-06-22 MY MYPI2017704883A patent/MY189472A/en unknown
- 2016-06-22 EA EA201890123A patent/EA034587B1/ru unknown
- 2016-06-22 GE GEAP201614679A patent/GEP20207075B/en unknown
- 2016-06-22 JO JOP/2016/0126A patent/JO3430B1/ar active
- 2016-06-22 PL PL16731158T patent/PL3313850T3/pl unknown
- 2016-06-22 TN TNP/2017/000521A patent/TN2017000521A1/en unknown
- 2016-06-22 CA CA2990089A patent/CA2990089C/en active Active
- 2016-06-22 JP JP2017566280A patent/JP6741698B2/ja active Active
- 2016-06-22 WO PCT/EP2016/064436 patent/WO2016207226A1/en active Application Filing
- 2016-06-23 AR ARP160101879A patent/AR105101A1/es unknown
-
2017
- 2017-12-07 IL IL256191A patent/IL256191B/en active IP Right Grant
- 2017-12-11 CL CL2017003163A patent/CL2017003163A1/es unknown
- 2017-12-11 PH PH12017502266A patent/PH12017502266A1/en unknown
- 2017-12-12 SV SV2017005588A patent/SV2017005588A/es unknown
- 2017-12-13 CO CONC2017/0012830A patent/CO2017012830A2/es unknown
- 2017-12-14 EC ECIEPI201782546A patent/ECSP17082546A/es unknown
- 2017-12-21 SA SA517390583A patent/SA517390583B1/ar unknown
-
2018
- 2018-07-26 HK HK18109702.0A patent/HK1250234A1/zh unknown
- 2018-09-06 HK HK18111502.8A patent/HK1252113B/zh unknown
- 2018-10-31 HR HRP20181806TT patent/HRP20181806T1/hr unknown
- 2018-12-10 CY CY181101321T patent/CY1120991T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012830A2 (es) | Compuestos de n-tieno [2,3-d] pirimidinil-d-fenilalanina, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CO2017012845A2 (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CO2017012832A2 (es) | Compuestos derivados de d-fenilalanina - n - sustituidos con bicíclicos aromáticos, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| PE20180521A1 (es) | Inhibidores de tirosina-cinasas | |
| PE20151064A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| BR112018011929A2 (pt) | composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto | |
| ECSP17057131A (es) | Desacetoxitubulisina h y análogos de esta | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| ECSP14014778A (es) | Composiciones derivadas de la quitosana | |
| BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
| CO2020003475A2 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| MD20160018A2 (ro) | Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| CY1122172T1 (el) | Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης | |
| UY36461A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos,composiciones que los contienen y usos de los mismos | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| NI201500172A (es) | Composiciones farmacéuticas | |
| ECSP17046657A (es) | Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina | |
| EA201792502A1 (ru) | Кабазитаксел и его применение для лечения рака |